keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RP-6685, a highly potent and selective inhibitor of DNA polymerase theta (Polθ), manifests remarkable oral activity. With an IC 50 value of 5.8 nM in the PicoGreen assay, RP-6685 effectively hinders the enzymatic activity of Polθ. In addition, it demonstrates significant antitumor efficacy as observed in a mouse tumor xenograft model [1].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,980 | 现货 | ||
5 mg | ¥ 4,890 | 现货 | ||
10 mg | ¥ 6,980 | 现货 | ||
25 mg | ¥ 9,870 | 现货 | ||
50 mg | ¥ 13,900 | 现货 | ||
100 mg | ¥ 18,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 5,330 | 现货 |
产品描述 | RP-6685, a highly potent and selective inhibitor of DNA polymerase theta (Polθ), manifests remarkable oral activity. With an IC 50 value of 5.8 nM in the PicoGreen assay, RP-6685 effectively hinders the enzymatic activity of Polθ. In addition, it demonstrates significant antitumor efficacy as observed in a mouse tumor xenograft model [1]. |
体外活性 | RP-6685 is extremely potent with an IC 50 of 550 pM against the pol activity of full-length Polθ whereas inactive on the ATPase activity [1]. RP-6685 inhibits Polθ in HEK293 LIG4 -/- cellswith an IC 50 of 0.94 μM [1]. |
体内活性 | RP-6685 (80 mg/kg; p.o.; BID for 21 days) shows potent antitumor efficacy in BRCA2-deficient HCT116 mice [1]. Animal Model: Female CD1 nude mice (HCT116 BRCA2 +/+ and BRCA2 -/- xenograft tumor models) [1] Dosage: 80 mg/kg Administration: p.o.; BID for 21 days Result: Showed tumor regression during the first 8 days of treatment in BRCA2 -/- HCT116 model, while did not inhibit tumor growth in BRCA2 +/+ HCT116 tumors mice. Animal Model: CD1 mice (20-30 g) [1] Dosage: 2.5 mg/kg Administration: i.v. or p.o.; single dosage Result: CL (mL/min/kg) V dss (L/kg) t 1/2 (h) F (%) 36.8 1.1 0.4 66 |
分子量 | 497.37 |
分子式 | C22H14F7N5O |
CAS No. | 2832047-80-8 |
keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 112.5 mg/mL (226.2 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0106 mL | 10.0529 mL | 20.1058 mL | 50.2644 mL |
5 mM | 0.4021 mL | 2.0106 mL | 4.0212 mL | 10.0529 mL | |
10 mM | 0.2011 mL | 1.0053 mL | 2.0106 mL | 5.0264 mL | |
20 mM | 0.1005 mL | 0.5026 mL | 1.0053 mL | 2.5132 mL | |
50 mM | 0.0402 mL | 0.2011 mL | 0.4021 mL | 1.0053 mL | |
100 mM | 0.0201 mL | 0.1005 mL | 0.2011 mL | 0.5026 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
RP-6685 2832047-80-8 Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA/RNA Synthesis RP 6685 RP6685 Inhibitor inhibitor inhibit